Filing Details
- Accession Number:
- 0001140361-15-004906
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-02-09 17:45:28
- Reporting Period:
- 2015-02-05
- Filing Date:
- 2015-02-09
- Accepted Time:
- 2015-02-09 17:45:28
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1302573 | Oncomed Pharmaceuticals Inc | OMED | Pharmaceutical Preparations (2834) | 383572512 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1553333 | Timothy Hoey | C/O Oncomed Pharmaceuticals, Inc. 800 Chesapeake Drive Redwood City CA 94063 | Svp, Cancer Biology | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2015-02-05 | 7,500 | $1.43 | 57,445 | No | 4 | M | Direct | |
Common Stock | Disposition | 2015-02-05 | 7,500 | $22.83 | 49,945 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2015-02-05 | 7,500 | $0.00 | 7,500 | $1.43 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
35,263 | 2017-01-10 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 20, 2013.
- This transaction was executed in multiple trades in prices ranging from $22.49 to $23.17, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The option is fully vested and exercisable, subject to a limitation of 175,438 shares that can be issued to a single grantee in a 12-month period upon the exercise of awards under the Issuer's 2004 Stock Incentive Plan.